The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Myopathy-Myositis-Polymyositis (see also under Xba)
May associate with myocarditis (PMID 30790071)
Publications
Kudo F, Watanabe Y, Iwai Y, Miwa C, Nagai Y, Ota H, Yabe H, Demitsu T, Hagiwara K, Koyama N, Koyama S
Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
Internal medicine (Tokyo, Japan) 2018 Aug 01;57;2217-2221 — 2018 Aug 01 — 2217-2221
[Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].
Revue de pneumologie clinique 2017 Dec;73;326-330 — 2017 Dec — 326-330
Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment.
Journal for immunotherapy of cancer 2017 07 18;5;54 — 2017 07 18 — 54